Verrica Pharmaceuticals Inc.
VRCA
Price:
$1.89
Market Cap:
$80.64M
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagio...[Read more]
Industry
Biotechnology
IPO Date
2018-06-15
Stock Exchange
NASDAQ
Ticker
VRCA
The ROE as of September 2024 (TTM) for Verrica Pharmaceuticals Inc. (VRCA) is -691.62%
According to Verrica Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is -691.62%. This represents a change of 97.80% compared to the average of -349.65% of the last 4 quarters.
Verrica Pharmaceuticals Inc. (VRCA) Historical ROE (quarterly & annually)
How has VRCA ROE performed in the past?
The mean historical ROE of Verrica Pharmaceuticals Inc. over the last ten years is -89.04%. The current -691.62% ROE has changed 676.76% with respect to the historical average. Over the past ten years (40 quarters), VRCA's ROE was at its highest in in the June 2024 quarter at 129.22%. The ROE was at its lowest in in the March 2024 quarter at -1344.64%.
Average
-89.04%
Median
-60.90%
Minimum
-338.99%
Maximum
71.81%
Verrica Pharmaceuticals Inc. (VRCA) ROE by Quarter and Year
Discovering the peaks and valleys of Verrica Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 390.31%
Maximum Annual ROE = 71.81%
Minimum Annual Increase = -173.34%
Minimum Annual ROE = -338.99%
| Year | ROE | Change |
|---|---|---|
| 2023 | -338.99% | 390.31% |
| 2022 | -69.14% | -42.05% |
| 2021 | -119.32% | -13.49% |
| 2020 | -137.93% | 220.84% |
| 2019 | -42.99% | 86.20% |
| 2018 | -23.09% | -56.16% |
| 2017 | -52.66% | -173.34% |
Verrica Pharmaceuticals Inc. (VRCA) Average ROE
How has VRCA ROE performed in the past?
The current ROE of Verrica Pharmaceuticals Inc. (VRCA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-175.82%
5-year avg
-141.67%
10-year avg
-89.04%
Verrica Pharmaceuticals Inc. (VRCA) ROE vs. Peers
How is VRCA’s ROE compared to its peers?
Verrica Pharmaceuticals Inc.’s ROE is greater than LianBio (-38.06%), less than Inventiva S.A. (550.46%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Vigil Neuroscience, Inc. (-76.02%), less than Connect Biopharma Holdings Limited (-3.40%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Eton Pharmaceuticals, Inc. (-43.62%), greater than Nuvation Bio Inc. (-98.79%), greater than Eledon Pharmaceuticals, Inc. (-124.74%), greater than Verona Pharma plc (-55.46%), less than Galera Therapeutics, Inc. (21.95%), greater than Arcutis Biotherapeutics, Inc. (-145.41%), greater than Protalix BioTherapeutics, Inc. (-45.15%), greater than Chinook Therapeutics, Inc. (-57.70%), greater than DICE Therapeutics, Inc. (-102.37%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), less than Ascendis Pharma A/S (251.76%), greater than Fennec Pharmaceuticals Inc. (-52.10%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Homology Medicines, Inc. (-100.91%),
| Company | ROE | Market cap |
|---|---|---|
| -38.06% | $34.47M | |
| 550.46% | $115.74M | |
| -28.01% | $1.59B | |
| -76.02% | $144.52M | |
| -3.40% | $65.75M | |
| -24.63% | $152.60M | |
| -43.62% | $141.71M | |
| -98.79% | $763.35M | |
| -124.74% | $105.09M | |
| -55.46% | $2.45B | |
| 21.95% | $3.76M | |
| -145.41% | $1.20B | |
| -45.15% | $79.43M | |
| -57.70% | $2.71B | |
| -102.37% | $2.27B | |
| -41.05% | $722.93M | |
| -62.63% | $4.34B | |
| 251.76% | $8.05B | |
| -52.10% | $142.57M | |
| -37.84% | $425.59M | |
| -100.91% | $3.02M |
Build a custom stock screener for Verrica Pharmaceuticals Inc. (VRCA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verrica Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Verrica Pharmaceuticals Inc. (VRCA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Verrica Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Verrica Pharmaceuticals Inc.'s ROE?
How is the ROE calculated for Verrica Pharmaceuticals Inc. (VRCA)?
What is the highest ROE for Verrica Pharmaceuticals Inc. (VRCA)?
What is the 3-year average ROE for Verrica Pharmaceuticals Inc. (VRCA)?
What is the 5-year average ROE for Verrica Pharmaceuticals Inc. (VRCA)?
How does the current ROE for Verrica Pharmaceuticals Inc. (VRCA) compare to its historical average?